Notably, compared to tumor cell types we have previously treated with neratinib as a single agent, we observed a profound increase in the phosphorylation of ULK1 S317 and profound reductions in the phosphorylation of ULK1 S757, mTORC1 S2448, mTORC2 S2481 and p70 S6K T389. The gene discussed is RPS6KB1; the disease is neoplasm.